H Lundbeck B (HLUNb)

Currency in DKK
43.62
-0.50(-1.13%)
Closed·
Advertisement
HLUNb is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
43.4644.12
52 wk Range
35.3047.78
Key Statistics
Prev. Close
44.12
Open
44.02
Day's Range
43.46-44.12
52 wk Range
35.3-47.78
Volume
255.91K
Average Volume (3m)
525.01K
1-Year Change
5.2606%
Book Value / Share
27.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HLUNb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
48.73
Upside
+11.72%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 4 consecutive years

H Lundbeck B News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

5 Buy
7 Hold
1 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 48.73
(+11.72% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Hold45.00+3.16%44.00Maintain20/08/2026
Barclays
Hold48.00+10.04%45.00Maintain17/07/2026
Jefferies
Hold39.00-10.59%35.00Upgrade02/03/2026
Deutsche Bank
Hold40.00-8.30%44.00Maintain18/02/2026
Barclays
Hold45.00+3.16%50.00Maintain12/02/2026

Earnings

Latest Release
19/08/2026
EPS / Forecast
1.16 / 1.12
Revenue / Forecast
6.46B / 6.19B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.97%
Dividend Yield
2.59%
Industry Median 3.65%
Annualised payout
1.15
Paid annually
5-Years Growth
+18.13%
Growth Streak

Compare HLUNb to Peers and Sector

Metrics to compare
HLUNb
Peers
Sector
Relationship
P/E Ratio
11.1x16.6x−0.4x
PEG Ratio
0.760.030.00
Price/Book
1.6x2.5x2.6x
Price / LTM Sales
1.7x2.9x3.0x
Upside (Analyst Target)
4.3%16.0%49.0%
Fair Value Upside
Unlock13.1%6.5%Unlock

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.

Employees
5000
Market
Denmark

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
99.51M10.04%4.39B
Other Institutional Investors
685.96M69.20%30.26B
Public Companies & Retail Investors
205.76M20.76%9.08B
Total
991.23M100.00%43.73B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Lundbeckfonden BioCapital69.11%685,069,88430,225,283
Polar Capital Holdings Plc2.14%21,234,056936,847

People Also Watch

2.705
DOMI
0.00%
5.110
EDRE
+3.13%
64.00
ALS
+0.25%
12.51
OPM
-1.73%

FAQ

What Is the H Lundbeck B (Copenhagen: HLUNb) Share Price Today?

The H Lundbeck B stock price today is 43.62 DKK.

What Stock Exchange Does H Lundbeck B (HLUNb) Trade On?

H Lundbeck B is listed and trades on the Copenhagen Stock Exchange.

What Is the Ticker (Stock Symbol) for H Lundbeck B?

The stock symbol (also called a 'ticker') for H Lundbeck B is "HLUNb."

Does H Lundbeck B Pay Dividends? What’s The Current HLUNb Dividend Yield?

Yes, HLUNb Pays Dividends to its Shareholders. The current H Lundbeck B dividend yield is 2.59%.

What Is the Current H Lundbeck B Market Capitalisation?

As of today, H Lundbeck B (Copenhagen: HLUNb) market cap is 43.18B DKK.

What Is H Lundbeck B's (HLUNb) Earnings Per Share (TTM)?

The H Lundbeck B EPS is currently 3.97 (Trailing Twelve Months).

When Is the Next H Lundbeck B Earnings Date?

H Lundbeck B's next earnings report will be released on 11/11/2026.

Is HLUNb a Buy or Sell From a Technical Analyst Perspective?

Based on today's H Lundbeck B moving averages and other technical indicators, the daily buy/sell signal for HLUNb stock is Strong Buy.

How Many Times Has H Lundbeck B Stock Split?

H Lundbeck B has split 0 times. (See the HLUNb stock split history page for full effective split date and price information.)

How Many Employees Does H Lundbeck B Have?

H Lundbeck B has 5000 employees, based on their latest Companies House report.

What is the current trading status of H Lundbeck B (Copenhagen: HLUNb)?

As of 08/09/2026, H Lundbeck B (HLUNb) is trading at a share price of 43.62 DKK, with a previous close of 44.12 DKK. The stock has fluctuated within a day range of 43.46 DKK to 44.12 DKK, while its 52-week range spans from 35.30 DKK to 47.78 DKK.

What Is H Lundbeck B (HLUNb) Price Target According to Analysts?

The average 12-month price target for H Lundbeck B is 48.73 DKK, with a high estimate of 65 DKK and a low estimate of 34 DKK. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +11.72% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.